‘More Money’ Could Move To OTC Monograph Process
This article was originally published in The Tan Sheet
Executive Summary
CDER Director Woodcock is “trying to figure out ways … to get more money into” FDA’s OTC monograph work.
You may also be interested in...
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: